Zerpidio (Serplulimab) sold under the brand name 汉斯状 in china.Serplulimab, a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection, is the first innovative monoclonal antibody developed by Henlius.
Chinese Version
Brand name：Zerpidio (汉斯状)
INN name：Serplulimab (斯鲁利单抗)
Manufacturer：Henlius Biotech (复宏汉霖)
Packaging：100mg(10ml)Bottle/Box
Inquire&E-mail: care@100pei.com
Serplulimab was launched in China in March 2022 and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, and esophageal squamous cell carcinoma (ESCC). Oct. 27, 2023 – Intas Pharma has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc.for the development and commercialisation of serplulimab for Europe and India markets. Jan. 2024 Zerpidio® in Indonesia for the treatment of extensive stage small cell lung cancer (ES-SCLC).
扫一扫 
